Lignocaine Infusion in Ventricular Tachycardia
For hemodynamically stable monomorphic VT, administer lignocaine (lidocaine) as an initial bolus of 1-1.5 mg/kg IV, followed by a maintenance infusion of 1-4 mg/min (typically 2 mg/min), with a maximum cumulative dose of 3 mg/kg. 1
Clinical Context and Drug Selection
Lignocaine is now considered a second-line agent for stable monomorphic VT in modern guidelines. The 2010 AHA guidelines classify it as a "relatively weak sodium channel blocker" and recommend procainamide or amiodarone as first-line options 1. However, lignocaine remains particularly useful when VT is associated with acute myocardial ischemia or infarction 2.
The evidence base shows lignocaine is significantly less effective than alternatives:
- Procainamide is 3.7 times more likely to terminate VT than lignocaine 3
- Ajmaline is 5.3 times more effective 3
- Sotalol is 3.9 times more effective 3
Dosing Algorithm
Initial Loading Dose
- 1-1.5 mg/kg IV bolus over 2-3 minutes 1
- For cardiac arrest: 100 mg bolus, repeatable after 5-10 minutes 4
- For stable VT with adverse signs: 50 mg over 2 minutes, repeated every 5 minutes to maximum total of 200 mg 4
Maintenance Infusion
- Standard rate: 2 mg/min after successful cardioversion 4
- Range: 1-4 mg/min (30-50 mcg/kg/min) 1
- Optimal rate for heart failure patients: 1 mg/min (achieves 78.6% probability of therapeutic levels) 5
Maximum Dosing Limits
- Maximum cumulative bolus dose: 3 mg/kg 1
- Without epinephrine: 4.5 mg/kg or 300 mg total 6
- With epinephrine: 7 mg/kg or 500 mg total 6
Critical Monitoring Requirements
Therapeutic Drug Monitoring
- Target plasma concentration: 1.5-5.0 μg/L 5
- Steady-state achieved in 3-4 hours in normal patients 7
- In myocardial infarction: 8-10 hours to steady state 7
- In heart failure: may take 24-48 hours, with continued rise in levels 7
Clinical Monitoring
Monitor continuously for:
- CNS toxicity (earliest signs): paresthesia, drowsiness, slurred speech, altered consciousness, muscular twitching, seizures 4, 6
- Cardiovascular effects: bradycardia, hypotension, myocardial depression 1
- Respiratory adequacy 6
Special Populations and Dose Adjustments
Heart Failure Patients
- Reduce maintenance infusion to 1 mg/min 5
- Decreased clearance and volume of distribution require lower loading and maintenance doses 7
- Plasma levels may continue rising for 24-48 hours 7
Hepatic Disease
- Use with extreme caution - lignocaine is metabolized exclusively by the liver 6, 7
- Reduced clearance necessitates dose reduction 7
- Lignocaine clearance is a sensitive marker of hepatic dysfunction 7
Elderly and Debilitated Patients
- Reduce both loading and maintenance doses 6
Common Pitfalls and Contraindications
Avoid Lignocaine When:
- Wide-QRS tachycardia of unknown origin - use procainamide instead 2
- Polymorphic VT with prolonged QT (torsades de pointes) - use magnesium instead 1
- No effect on supraventricular tachycardia - completely ineffective 4
Critical Timing Issue
The subtherapeutic gap problem: Traditional bolus-then-infusion creates a dangerous drop in plasma levels between peak bolus concentration and steady-state infusion levels 8. This gap allows breakthrough arrhythmias. Consider using a continuous infusion at 25 mg/min with weight-based dosing to eliminate this hiatus 8.
Response Assessment
In chronic VPBs, do not assess response before 8 hours - the antiarrhythmic effect is significantly delayed compared to acute-onset VPBs, where response occurs within the first hour 9. Making premature decisions about efficacy leads to inappropriate drug changes.
Drug Interactions
- Avoid with MAO inhibitors or tricyclic antidepressants if epinephrine is co-administered (risk of severe hypertension) 6
- Beta-blockers may mask tachycardia from accidental intravascular injection 6
Administration Technique
- Always flush with 20 mL saline after peripheral IV administration to ensure central circulation delivery 4
- Avoid rapid bolus injection - administer over 2-3 minutes to minimize toxicity risk
- For refractory or recurrent VT, consider electrical cardioversion or transvenous pacing rather than escalating lignocaine doses 2